Innvierte, a venture capital firm, led a €13m Series C funding round in DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, with participation from Kurma Partners, Alta Life Sciences, UI Investissement and Axis Participaciones Empresariales. “Early identification of sepsis is absolutely crucial to a patient’s prognosis, but the tools caregivers have available today are woefully inadequate. Our mission is to change this and this financing will allow us to ramp up our efforts to bring our first-in-class sepsis recognition platform to market. We are grateful to our existing investors and excited to welcome our new investors, that strengthen our investor base,” Jordi Carrera, DeepUll CEO and Co-Founder.